Ask AI

Redefining Success: Individualizing HBV Care

Video
This activity is available for 1.50 CME/CE credit(s).

Released: November 19, 2026

Expiration: November 18, 2027

See Activity Collection

Antiviral therapies for hepatitis B virus (HBV) infection effectively suppress viral replication but rarely lead to loss of HBsAg or functional cure. Recently, experts proposed a stepwise framework of individualized endpoints to redefine HBV treatment ranging from durable on-treatment suppression to partial cure to functional cure, based on patient-specific factors and biomarker profiles. This webcast explores the current state of HBV treatment and monitoring and examines ways to individualize therapy goals with new and upcoming agents.

Individualizing HBV Care

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with HBV do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

If you practice in gastroenterology or hepatology, please indicate your specialty:

4.

In people with immune-tolerant HBeAg+ CHB, long-term treatment with NAs was associated with viral suppression (DNA <300 c/mL) in approximately:

5.

If following the FDA indication, in which person with CHB would you recommend bepirovirsen to try to achieve functional cure?

6.

In an open-label clinical trial of people with HBeAg+ CHB, treatment with pevifoscorvir was associated with declines in: